Robert P. Giugliano

60.2k total citations · 20 hit papers
558 papers, 33.3k citations indexed

About

Robert P. Giugliano is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Robert P. Giugliano has authored 558 papers receiving a total of 33.3k indexed citations (citations by other indexed papers that have themselves been cited), including 391 papers in Cardiology and Cardiovascular Medicine, 244 papers in Surgery and 80 papers in Internal Medicine. Recurrent topics in Robert P. Giugliano's work include Acute Myocardial Infarction Research (184 papers), Atrial Fibrillation Management and Outcomes (176 papers) and Lipoproteins and Cardiovascular Health (145 papers). Robert P. Giugliano is often cited by papers focused on Acute Myocardial Infarction Research (184 papers), Atrial Fibrillation Management and Outcomes (176 papers) and Lipoproteins and Cardiovascular Health (145 papers). Robert P. Giugliano collaborates with scholars based in United States, United Kingdom and Canada. Robert P. Giugliano's co-authors include Eugene Braunwald, Marc S. Sabatine, Elliott M. Antman, Sabina A. Murphy, Christian T. Ruff, Eugene Braunwald, Stephen D. Wiviott, Basil S. Lewis, David A. Morrow and Carolyn H. McCabe and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Robert P. Giugliano

535 papers receiving 32.3k citations

Hit Papers

Comparison of the efficac... 2000 2026 2008 2017 2013 2015 2000 2015 2016 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
    2013 3.3k citations Christian T. Ruff, Robert P. Giugliano et al. profile →
  2. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    2015 2.9k citations Michael A. Blazing, Robert P. Giugliano et al. New England Journal of Medicine profile →
  3. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation
    2000 1.1k citations David A. Morrow, Elliott M. Antman et al. Circulation profile →
  4. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
  5. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
    2016 975 citations Stephen D. Wiviott, Robert P. Giugliano et al. profile →
  6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
    2019 585 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →
  7. Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes
    2005 539 citations Marc S. Sabatine, David A. Morrow et al. Circulation profile →
  8. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
    2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
  9. Variation inPCSK9andHMGCRand Risk of Cardiovascular Disease and Diabetes
    2016 491 citations Jennifer G. Robinson, Robert P. Giugliano et al. New England Journal of Medicine profile →
  10. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
    2017 469 citations Robert P. Giugliano, Terje R. Pedersen et al. profile →
  11. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
    2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. profile →
  12. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
    2012 354 citations Robert P. Giugliano, Ransi Somaratne et al. profile →
  13. Cognitive Function in a Randomized Trial of Evolocumab
    2017 329 citations Robert P. Giugliano, François Mach et al. New England Journal of Medicine profile →
  14. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
    2015 299 citations Christian T. Ruff, Robert P. Giugliano et al. profile →
  15. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
    2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology profile →
  16. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
    2022 211 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →
  17. Lipoprotein(a) and its Significance in Cardiovascular Disease
    2022 182 citations Robert P. Giugliano et al. profile →
  18. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
    2024 102 citations Brian A. Bergmark, Nicholas Marston et al. New England Journal of Medicine profile →
  19. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations
    2024 44 citations Giorgio Melloni, Benjamin M. Scirica et al. profile →
  20. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
    2025 31 citations Siddharth M. Patel, Robert P. Giugliano et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert P. Giugliano United States 86 18.9k 15.9k 4.9k 4.8k 4.6k 558 33.3k
Sabina A. Murphy United States 97 30.0k 1.6× 17.9k 1.1× 1.9k 0.4× 8.1k 1.7× 5.8k 1.3× 487 43.5k
Stephen D. Wiviott United States 63 23.1k 1.2× 17.8k 1.1× 2.8k 0.6× 12.1k 2.5× 4.9k 1.1× 206 37.8k
Marc S. Sabatine United States 107 27.9k 1.5× 22.8k 1.4× 3.9k 0.8× 13.3k 2.8× 3.3k 0.7× 512 51.0k
Carolyn H. McCabe United States 80 29.7k 1.6× 17.3k 1.1× 2.0k 0.4× 2.9k 0.6× 5.1k 1.1× 182 38.6k
Colin Baigent United Kingdom 51 8.9k 0.5× 11.0k 0.7× 3.7k 0.8× 4.7k 1.0× 1.6k 0.4× 136 22.6k
Basil S. Lewis Israel 52 20.1k 1.1× 8.6k 0.5× 2.2k 0.4× 2.9k 0.6× 6.9k 1.5× 278 28.0k
Eugene Braunwald United States 104 43.0k 2.3× 20.7k 1.3× 3.2k 0.7× 5.6k 1.2× 4.5k 1.0× 448 59.7k
Ulf Landmesser Germany 86 15.2k 0.8× 10.8k 0.7× 1.8k 0.4× 4.4k 0.9× 950 0.2× 574 34.0k
Christopher P. Cannon United States 125 38.0k 2.0× 27.9k 1.8× 5.3k 1.1× 14.2k 3.0× 3.9k 0.8× 879 67.5k
Pierre Théroux Canada 74 19.0k 1.0× 10.2k 0.6× 1.5k 0.3× 2.1k 0.4× 3.1k 0.7× 273 26.4k

Countries citing papers authored by Robert P. Giugliano

Since Specialization
Citations

This map shows the geographic impact of Robert P. Giugliano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert P. Giugliano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert P. Giugliano more than expected).

Fields of papers citing papers by Robert P. Giugliano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert P. Giugliano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert P. Giugliano. The network helps show where Robert P. Giugliano may publish in the future.

Co-authorship network of co-authors of Robert P. Giugliano

This figure shows the co-authorship network connecting the top 25 collaborators of Robert P. Giugliano. A scholar is included among the top collaborators of Robert P. Giugliano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert P. Giugliano. Robert P. Giugliano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maranhão, Raul Cavalcante, Rocío Salsoso, Remo H.M. Furtado, et al.. (2025). Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction. IJC Heart & Vasculature. 60. 101771–101771.
2.
Wallentin, Lars, Johan Lindbäck, Ziad Hijazi, et al.. (2025). Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 85(11). 1173–1185. 1 indexed citations
3.
Bergmark, Regan W., Sabina A. Murphy, Martin Unverdorben, et al.. (2025). Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial. Journal of the American Heart Association. 14(2). e031434–e031434.
4.
Marston, Nicholas, Frederick Kamanu, Giorgio Melloni, et al.. (2025). Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering. Nature Medicine. 31(3). 963–969. 4 indexed citations
5.
Johnson, Linda, Alexander P. Benz, Ashkan Shoamanesh, et al.. (2024). Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF. Journal of the American Heart Association. 13(17). e034758–e034758. 3 indexed citations
6.
Haller, Paul M., Petr Jarolı́m, Andrea Bellavia, et al.. (2024). Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 84(16). 1528–1540. 7 indexed citations
7.
Zoccali, Carmine, Francesca Mallamaci, Jean‐Michel Halimi, et al.. (2024). Author Correction: Chronic cardiovascular–kidney disorder: a new conceptual framework. Nature Reviews Nephrology. 20(4). 266–266. 1 indexed citations
8.
Benz, Alexander P., Stefan H. Hohnloser, John W. Eikelboom, et al.. (2023). Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44(20). 1807–1814. 23 indexed citations
9.
O’Donoghue, Michelle L., Robert P. Giugliano, Stephen D. Wiviott, et al.. (2022). Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 146(15). 1109–1119. 211 indexed citations breakdown →
10.
Lau, Emily S., Eugene Braunwald, David A. Morrow, et al.. (2021). Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation. 143(7). 685–695. 20 indexed citations
11.
Groot, Joris R. de, Christian T. Ruff, Sabina A. Murphy, et al.. (2021). Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. American Heart Journal. 235. 132–139. 6 indexed citations
12.
Giugliano, Robert P., Terje R. Pedersen, Jeffrey L. Saver, et al.. (2020). Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 51(5). 1546–1554. 114 indexed citations
13.
Marston, Nicholas, Yared Gurmu, Giorgio Melloni, et al.. (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 141(20). 1600–1607. 65 indexed citations
14.
Bohula, Erin A., Robert P. Giugliano, Lawrence A. Leiter, et al.. (2018). Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 138(2). 131–140. 193 indexed citations
15.
Bohula, Erin A., Stephen D. Wiviott, Robert P. Giugliano, et al.. (2017). Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 136(25). 2440–2450. 82 indexed citations
16.
Bonaca, Marc P., Patrice Nault, Robert P. Giugliano, et al.. (2017). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 137(4). 338–350. 491 indexed citations breakdown →
17.
Blazing, Michael A., Robert P. Giugliano, Jennifer A. White, et al.. (2015). Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 372(25). 2387–2397. 2870 indexed citations breakdown →
18.
Sabatine, Marc S., Robert P. Giugliano, Stephen D. Wiviott, et al.. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 372(16). 1500–1509. 1091 indexed citations breakdown →
19.
20.
Piccini, Jonathan P., Jennifer A. White, Rajendra H. Mehta, et al.. (2012). Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes. Circulation. 126(1). 41–49. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabina A. Murphy Breakdown of academic impact, for papers by Stephen D. Wiviott Breakdown of academic impact, for papers by Marc S. Sabatine Breakdown of academic impact, for papers by Carolyn H. McCabe Breakdown of academic impact, for papers by Colin Baigent Breakdown of academic impact, for papers by Basil S. Lewis Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Ulf Landmesser Breakdown of academic impact, for papers by Christopher P. Cannon Breakdown of academic impact, for papers by Pierre Théroux
Rankless by CCL
2026